

# 4<sup>th</sup>

# INTERNATIONAL CONFERENCE ON CONTROVERSIES IN VITAMIN D



With an unrestricted contribution of



## ORGANIZING SECRETARIAT


**A.I.C. - Asti Incentives & Congressi**

Piazza San Uomobono, 30 - 56126 (Pisa) - Ph +39 050 598808 - Fax +39 050 0987825

Email: [vitaminD2020@aicgroup.it](mailto:vitaminD2020@aicgroup.it)

# WEBINAR

## 23<sup>rd</sup> - 25<sup>th</sup> September 2020



## Wednesday, 23<sup>rd</sup> September 2020

	<b>Morning</b> (Italian time) <b>RECORDED SESSIONS</b>
	<b>Keynote Lectures</b> <b>Chairs:</b> J.P. Bilezikian (USA), A. Giustina (Italy)
10.00-10.25 am	Vitamin D physiology revisited - D. Bikle (USA)
10.25-10.50 am	Nutritional rickets in 2020 - P. Lips (The Netherlands)
10.50-11.15 am	Vitamin D in the Covid-19 Era - A.M. Formenti (Italy)
	<b>Afternoon</b> (Italian time) <b>LIVE SESSIONS</b>
1.55-2.00 pm	Welcome Address - Roadmap and goals of the meeting J.P. Bilezikian (USA) - A. Giustina (Italy)
2.00-3.00 pm	<b>Laboratory 1</b> <b>Chairs:</b> C. Sempos (USA) - <b>Moderator:</b> J. Virtanen (Finland)
2.00-2.20 pm	To whom should we administer vitamin D without assaying it P. Ebeling (Australia)
2.20-2.40 pm	To whom should we administer vitamin D after assaying it G. El-Hajj Fuleihan (Lebanon)
2.40-3.00 pm	Open Discussion
3.00-4.20 pm	<b>Laboratory 2:</b> <b>Chairs:</b> G. Jones (Canada) - <b>Moderator:</b> D. Bikle (USA)
3.00-3.20 pm	Assays - A. Heijboer (The Netherlands)
3.20-3.40 pm	Threshold for the general population - N. Binkley (USA)
3.40-4.00 pm	Thresholds for special populations - J. Bilezikian (USA)
4.00-4.20 pm	Open Discussion
4.20-6.00 pm	<b>Meeting of the Laboratory working group</b> <b>Coordinators:</b> N. Binkley (USA), C. Sempos (USA)

## Thursday, 24<sup>th</sup> September 2020

	<b>Afternoon</b> (Italian time) <b>LIVE SESSIONS</b>
2.00-3.20 pm	<b>Clinical 1: Effects of Vitamin D deficiency and supplementation</b> <b>Chair:</b> C. Marcocci (Italy) - <b>Moderator:</b> J. Bollerslev (Norway)
2.00-2.15 pm	Cardiovascular and diabetes: effects of deficiency R. Scragg (New Zealand)

2.15-2.30 pm	Cardiovascular and diabetes: effects of supplementation - A. Pittas (USA)
2.30-2.45 pm	Autoimmunity: effects of deficiency - R. Bouillon (Belgium)
2.45-3.00 pm	Autoimmunity: effects of supplementation - J. H. White (Canada)
3.00-3.20 pm	<b>Open Discussion</b>
3.20-4.40 pm	<b>Clinical 2: Effects of Vitamin D deficiency and supplementation</b> <b>Chair:</b> R. Bouillon (Belgium) - <b>Moderator:</b> A. Pittas (USA)
3.20-3.35 pm	Musculoskeletal: effects of deficiency - R. Rizzoli (Switzerland)
3.35-3.50 pm	Musculoskeletal: effects of supplementation - B. Dawson Hughes (USA)
3.50-4.05 pm	Oncology: effects of deficiency - D. Feldman (USA)
4.05-4.20 pm	Oncology: effects of supplementation - M. Lazaretti Castro (Brazil)
4.20-4.40 pm	<b>Open discussion</b>
4.40-6.00 pm	<b>Meeting of the Clinical working group</b> <b>Coordinators:</b> R. Bouillon (Belgium), C. Marcocci (Italy)

## Friday, 25<sup>th</sup> September 2020

	<b>Afternoon</b> (Italian time) <b>LIVE SESSIONS</b>
2.00-2.45 pm	<b>Therapeutics 1: What Forms of Vitamin D?</b> <b>Chairs:</b> R. Rizzoli (Switzerland) - <b>Moderator:</b> S. Minisola (Italy)
2.00-2.15 pm	Ergocalciferol - N. Binkley (USA)
2.15-2.30 pm	Cholecalciferol - S. Giannini (Italy) <b>RECORDED</b>
2.30-2.45 pm	Active metabolites - C. Marcocci (Italy)
2.45-4.00 pm	<b>Therapeutics 2: Vitamin D Doses and modalities of administration</b> <b>Chair:</b> U. Liberman (Israel) - <b>Moderator:</b> R. Adler (USA)
2.45-3.00 pm	Pharmacokinetic/pharmacodynamic of cholecalciferol D. Gatti / A. Fassio (Italy)
3.00-3.15 pm	Route of administration, doses and Intervals when loading - N. Napoli (Italy)
3.15-3.30 pm	Route of administration, doses and Intervals when maintaining S. Minisola (Italy)
3.30-3.45 pm	<b>Open discussion</b>
3.45-5.00 pm	<b>Meeting of the Therapeutics working group</b> <b>Coordinators:</b> R. Adler (USA), R. Rizzoli (Switzerland)
5.15-6.30 pm	<b>Working Group Reports - Group Coordinators</b> <b>Consensus Statements - All participants</b>
6.30 pm	<b>Closing remarks and next steps - J.P. Bilezikian (USA), A. Giustina (Italy)</b>